These authors also stated that glypican-4 levels correlated with cardiometabolic risk factors, including insulin resistance and arterial stiffness, and the measurements were independently associated with non-alcoholic fatty liver disease, in women. Here, GPC4 is linked to metabolic dysfunction-associated steatotic liver disease.